These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 29018251)

  • 1. Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients.
    Wu PF; Liu WL; Hsieh MH; Hii IM; Lee YL; Lin YT; Ho MW; Liu CE; Chen YH; Wang FD
    Emerg Microbes Infect; 2017 Oct; 6(10):e87. PubMed ID: 29018251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing epidemiology of candidemia in a medical center in middle Taiwan.
    Hii IM; Chang HL; Lin LC; Lee YL; Liu YM; Liu CE; Chen CH; Cheng YR; Chang CY
    J Microbiol Immunol Infect; 2015 Jun; 48(3):306-15. PubMed ID: 24113067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).
    Arastehfar A; Yazdanpanah S; Bakhtiari M; Fang W; Pan W; Mahmoudi S; Pakshir K; Daneshnia F; Boekhout T; Ilkit M; Perlin DS; Zomorodian K; Zand F
    Med Mycol; 2021 May; 59(5):422-430. PubMed ID: 32692816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region.
    Tan TY; Hsu LY; Alejandria MM; Chaiwarith R; Chinniah T; Chayakulkeeree M; Choudhury S; Chen YH; Shin JH; Kiratisin P; Mendoza M; Prabhu K; Supparatpinyo K; Tan AL; Phan XT; Tran TT; Nguyen GB; Doan MP; Huynh VA; Nguyen SM; Tran TB; Van Pham H
    Med Mycol; 2016 Jul; 54(5):471-7. PubMed ID: 26868904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
    Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR
    J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.
    Taj-Aldeen SJ; Kolecka A; Boesten R; Alolaqi A; Almaslamani M; Chandra P; Meis JF; Boekhout T
    Infection; 2014 Apr; 42(2):393-404. PubMed ID: 24352810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: An Update From the CHIF-NET Study.
    Xiao M; Chen SC; Kong F; Xu XL; Yan L; Kong HS; Fan X; Hou X; Cheng JW; Zhou ML; Li Y; Yu SY; Huang JJ; Zhang G; Yang Y; Zhang JJ; Duan SM; Kang W; Wang H; Xu YC
    J Infect Dis; 2020 Mar; 221(Suppl 2):S139-S147. PubMed ID: 32176789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.
    Lin S; Chen R; Zhu S; Wang H; Wang L; Zou J; Yan J; Zhang X; Farmakiotis D; Tan X; Mylonakis E
    Mycopathologia; 2018 Aug; 183(4):679-689. PubMed ID: 29572768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida tropicalis is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures.
    Megri Y; Arastehfar A; Boekhout T; Daneshnia F; Hörtnagl C; Sartori B; Hafez A; Pan W; Lass-Flörl C; Hamrioui B
    Antimicrob Resist Infect Control; 2020 Apr; 9(1):50. PubMed ID: 32264966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes.
    Rodriguez L; Bustamante B; Huaroto L; Agurto C; Illescas R; Ramirez R; Diaz A; Hidalgo J
    PLoS One; 2017; 12(4):e0175172. PubMed ID: 28419092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
    Tadec L; Talarmin JP; Gastinne T; Bretonnière C; Miegeville M; Le Pape P; Morio F
    Mycoses; 2016 May; 59(5):296-303. PubMed ID: 26806101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China.
    Xiao Z; Wang Q; Zhu F; An Y
    Antimicrob Resist Infect Control; 2019; 8():89. PubMed ID: 31161036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of bloodstream Candida species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA®) for rapid diagnosis of candidemia.
    Falces-Romero I; Romero-Gómez MP; Moreno-Ramos F; Mingorance J; García-Rodríguez J; Cendejas-Bueno E
    Med Mycol; 2021 Apr; 59(4):350-354. PubMed ID: 32634233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study.
    Breda GL; Tuon FF; Meis JF; Herkert PF; Hagen F; de Oliveira LZ; Dias VC; da Cunha CA; Queiroz-Telles F
    Med Mycol; 2018 Jun; 56(4):406-415. PubMed ID: 29420820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
    Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
    J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil.
    Canela HMS; Cardoso B; Vitali LH; Coelho HC; Martinez R; Ferreira MEDS
    Mycoses; 2018 Jan; 61(1):11-21. PubMed ID: 28940753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait.
    Khan Z; Ahmad S; Al-Sweih N; Mokaddas E; Al-Banwan K; Alfouzan W; Al-Obaid I; Al-Obaid K; Asadzadeh M; Jeragh A; Joseph L; Varghese S; Vayalil S; Al-Musallam O
    PLoS One; 2019; 14(5):e0216250. PubMed ID: 31042770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.